The commercial failure of Biogen Inc.’s drug Aduhelm is putting new focus on the state of research into the causes of Alzheimer’s disease.
More than six million people in the U.S. are living with the progressive type of dementia, according to the Alzheimer’s Association, an advocacy group.
